Company Filing History:
Years Active: 2012-2021
Title: Zvi Fishelson: Innovator in Cancer Prognosis and Treatment
Introduction
Zvi Fishelson is a notable inventor based in Tel Aviv, Israel. He has made significant contributions to the field of cancer research, particularly in the development of methods and kits for predicting cancer prognosis. With a total of 3 patents to his name, Fishelson's work is at the forefront of innovative medical solutions.
Latest Patents
One of Fishelson's latest patents involves methods and kits for predicting the prognosis of cancer using soluble mortalin in blood. This patent provides methods for determining the presence or level of soluble mortalin in a body fluid of a subject. It also predicts the prognosis of a subject diagnosed with cancer by assessing the presence or level of soluble mortalin. Additionally, the patent includes kits designed for this purpose, which comprise at least two distinct antibodies to mortalin directed against different epitopes.
Another significant patent by Fishelson focuses on the down-regulation of mortalin by siRNA. This patent discloses the use of a siRNA molecule for treating diseases associated with pathological cell populations. It also includes pharmaceutical compositions and articles of manufacture that comprise the siRNAs, showcasing his innovative approach to cancer treatment.
Career Highlights
Throughout his career, Zvi Fishelson has worked with esteemed institutions such as Ramot at Tel Aviv University Ltd. and Semmelweis University. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Fishelson's notable coworkers include David Pilzer and Zoltan Prohaszka. Their collaborative efforts have further advanced the research and development of cancer prognosis and treatment methodologies.
Conclusion
Zvi Fishelson's contributions to cancer research through his innovative patents highlight his role as a key inventor in the medical field. His work continues to pave the way for advancements in cancer prognosis and treatment, making a significant impact on patient care.